Dihydrocodeine 30mg tablets

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktīvā sastāvdaļa:

Dihydrocodeine tartrate

Pieejams no:

M & A Pharmachem Ltd

ATĶ kods:

N02AA08

SNN (starptautisko nepatentēto nosaukumu):

Dihydrocodeine tartrate

Deva:

30mg

Zāļu forma:

Oral tablet

Ievadīšanas:

Oral

Klase:

Schedule 5 (CD Inv)

Receptes veids:

Valid as a prescribable product

Produktu pārskats:

BNF: 04070200; GTIN: 5056205100200 5056205100217

Lietošanas instrukcija

5HDGDOORIWKLVOHDIOHWFDUHIXOO\EHIRUH\RXVWDUWWDNLQJ
WKLVPHGLFLQHEHFDXVHLWFRQWDLQVLPSRUWDQWLQIRUPDWLRQ
IRU\RX


.HHSWKLVOHDIOHW

Izlasiet visu dokumentu

Produkta apraksts

OBJECT 1
DIHYDROCODEINE 30MG TABLETS
Summary of Product Characteristics Updated 20-Jun-2019 | M & A
Pharmachem Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Dihydrocodeine Tablets BP 30 mg
2. Qualitative and quantitative composition
Each tablet contains 30 mg Dihydrocodeine Tartrate
3. Pharmaceutical form
Tablet
4. Clinical particulars
4.1 Therapeutic indications
Dihydrocodeine tablets are indicated for the relief of moderate to
severe pain.
4.2 Posology and method of administration
For oral administration
The analgesic effect is not materially enhanced by increasing the dose
above that recommended below; in
severe cases the interval between doses should be reduced to obtain
the requisite analgesic cover.
Dihydrocodeine tablets are best taken with or after food.
Adults and children over 12 years: 1 tablet every four to six hours or
at the discretion of the practitioner.
Maximum dose in 24 hours 180mg (6 tablets).
Elderly
A reduced adult dose is recommended, at the